AstraZeneca CEO Pascal Soriot (Pascal Soriot) said on May 21 that drug sales and innovation in China will help the company achieve its new revenue target of $80 billion by 2030. Soliot said that AstraZeneca has set up a manufacturing facility in Qingdao to serve only China and other emerging markets, and he said the company “is working to establish a supply chain focused on China.”
阿斯利康将在中国打造单独供应链
AstraZeneca will create a separate supply chain in China
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.